This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, A. L.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 08 1996, 1948-1949, Vol 40, No. 8
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

In vitro studies of two triazole antifungal agents (voriconazole [UK- 109,496] and fluconazole) against Candida species

AL Barry and SD Brown
Clinical Microbiology Institute, Tualatin, Oregon 97062, USA.

A new triazole derivative (voriconazole or UK-109,496) and fluconazole were tested against 249 isolates of Candida spp. representing six species. Voriconazole was 10 to 100 times more potent than fluconazole. Strains with decreased susceptibility to fluconazole were inhibited by relatively low concentrations of voriconazole.


This article has been cited by other articles:

  • Armstrong-James, D. (2007). Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J Antimicrob Chemother 60: 459-460 [Abstract] [Full Text]  
  • Pascual, A., Nieth, V., Calandra, T., Bille, J., Bolay, S., Decosterd, L. A., Buclin, T., Majcherczyk, P. A., Sanglard, D., Marchetti, O. (2007). Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. Antimicrob. Agents Chemother. 51: 137-143 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A, Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Troke, P., Walsh, T. J., Warnock, D. W. (2006). Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints.. J. Clin. Microbiol. 44: 819-826 [Abstract] [Full Text]  
  • Serrano, M. C., Ramirez, M., Morilla, D., Valverde, A., Chavez, M., Espinel-Ingroff, A., Claro, R., Fernandez, A., Almeida, C., Martin-Mazuelos, E. (2004). A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.. J Antimicrob Chemother 53: 739-742 [Abstract] [Full Text]  
  • Serrano, M. C., Morilla, D., Valverde, A., Chavez, M., Espinel-Ingroff, A., Claro, R., Ramirez, M., Mazuelos, E. M. (2003). Comparison of Etest with Modified Broth Microdilution Method for Testing Susceptibility of Aspergillus spp. to Voriconazole. J. Clin. Microbiol. 41: 5270-5272 [Abstract] [Full Text]  
  • Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N. R., Smith, D. A., Walker, D. K., Wood, N. (2003). THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN. Drug Metab. Dispos. 31: 731-741 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Hollis, R. J., Jones, R. N. (2003). In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood. J. Clin. Microbiol. 41: 78-83 [Abstract] [Full Text]  
  • Venkataramanan, R., Zang, S., Gayowski, T., Singh, N. (2002). Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. Antimicrob. Agents Chemother. 46: 3091-3093 [Abstract] [Full Text]  
  • Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., Kleinermans, D. (2002). Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens. Antimicrob. Agents Chemother. 46: 2546-2553 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Perea, S., Coco, B. J., Patterson, T. F. (2002). Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 46: 2564-2568 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • PELLETIER, R., LORANGER, L., MARCOTTE, H., DE CAROLIS, E. (2002). Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 51: 479-483 [Abstract] [Full Text]  
  • Perea, S., Fothergill, A. W., Sutton, D. A., Rinaldi, M. G. (2001). Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method. J. Clin. Microbiol. 39: 385-388 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Rinaldi, M. G., Patterson, T. F. (2000). Efficacy of Voriconazole in a Guinea Pig Model of Disseminated Invasive Aspergillosis. Antimicrob. Agents Chemother. 44: 2865-2868 [Abstract] [Full Text]  
  • Perea, S., Pennick, G. J., Modak, A., Fothergill, A. W., Sutton, D. A., Sheehan, D. J., Rinaldi, M. G. (2000). Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma. Antimicrob. Agents Chemother. 44: 1209-1213 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Baran, J. Jr., Klauber, E., Barczak, J., Riederer, K., Khatib, R. (2000). Trends in Antifungal Susceptibility among Candida sp. Urinary Isolates from 1994 and 1998. J. Clin. Microbiol. 38: 870-871 [Abstract] [Full Text]  
  • Chavez, M., Bernal, S., Valverde, A., Gutierrez, M. J., Quindos, G., Mazuelos, E. M. (1999). In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44: 697-700 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Rex, J. H. (1999). Optimizing Voriconazole Susceptibility Testing of Candida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility. J. Clin. Microbiol. 37: 2755-2759 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., Ghannoum, M. A. (1999). In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43: 169-171 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., Hajjeh, R. A. (1998). In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole. Antimicrob. Agents Chemother. 42: 3242-3244 [Abstract] [Full Text]  
  • Vazquez, J. A., Arganoza, M. T., Boikov, D., Yoon, S., Sobel, J. D., Akins, R. A. (1998). Stable Phenotypic Resistance of Candida Species to Amphotericin B Conferred by Preexposure to Subinhibitory Levels of Azoles. J. Clin. Microbiol. 36: 2690-2695 [Abstract] [Full Text]  
  • McGinnis, M. R., Pasarell, L. (1998). In Vitro Testing of Susceptibilities of Filamentous Ascomycetes to Voriconazole, Itraconazole, and Amphotericin B, with Consideration of Phylogenetic Implications. J. Clin. Microbiol. 36: 2353-2355 [Abstract] [Full Text]  
  • Girmenia, C., Luzi, G., Monaco, M., Martino, P. (1998). Use of Voriconazole in Treatment of Scedosporium apiospermum Infection: Case Report. J. Clin. Microbiol. 36: 1436-1438 [Abstract] [Full Text]  
  • Vora, S., Purimetla, N., Brummer, E., Stevens, D. A. (1998). Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans: Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor. Antimicrob. Agents Chemother. 42: 907-910 [Abstract] [Full Text]  
  • Nguyen, M. H., Yu, C. Y. (1998). In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates. Antimicrob. Agents Chemother. 42: 471-472 [Abstract] [Full Text]  
  • Marco, F., Pfaller, M. A., Messer, S., Jones, R. N. (1998). In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 42: 161-163 [Abstract] [Full Text]  
  • Espinel-Ingroff, A (1998). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [In Process Citation]. J. Clin. Microbiol. 36: 198-202 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»